Recurrent Head and Neck Cancer Clinical Trial
Official title:
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
Verified date | February 2020 |
Source | Rakuten Medical, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a two-part clinical study of patients with recurrent Head and Neck Cancer (HNC), who
in the opinion of their physician, cannot be satisfactorily treated with surgery, radiation
or platinum chemotherapy. The purpose of the study is to determine the safety and anti-cancer
activity of various doses and repeated cycles of the experimental treatment using the study
drug RM-1929 and fixed amounts of red light applied at the tumor site to activate the
pharmacodynamics of the drug.
The part 1 of the study has been completed and consisted in a single cycle, 3+3 dose
escalation safety study of the experimental drug RM-1929 using a fixed amount of 690 nm red
light. The part 1 was designed to determine the safety of the treatment as set by the maximal
feasible dose or the maximal tolerable dose of RM-1929. From the part 1 results, the maximal
feasible dose of RM-1929 was determined.
The part 2 of the study is currently ongoing and it is evaluating the safety and anticancer
efficacy of up to four repeated treatments of Photoimmunotherapy with RM-1929 at the maximal
feasible dose of RM-1929 activated with a fixed amount of red light.
Status | Completed |
Enrollment | 40 |
Est. completion date | February 25, 2019 |
Est. primary completion date | February 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients must meet the following criteria to be eligible for study participation: 1. Patients with recurrent squamous carcinoma of the Head and Neck, who in the opinion of their treating physician, cannot be satisfactorily treated with surgery, radiation, or platinum chemotherapy. Diagnosis must be confirmed by biopsy and histopathology. 2. Patient must have received prior systemic platinum-based chemotherapy for treatment of their head and neck cancer, unless in the opinion of the medical oncologist, the use of platinum-based chemotherapy is contraindicated or not recommended, e.g., renal impairment, allergy to platinum compounds, age, liver disease, myelosuppression, neuropathy, hearing loss, etc. 3. Patients must have life expectancy > 6 months based on investigator judgment. 4. Male or female patients at least 18 years old. Female patients must not be pregnant or breast feeding and must be practicing a medically acceptable form of birth control, be sterile, or post-menopausal. Females of childbearing potential (FCBP) is defined as premenopausal women capable of becoming pregnant. This includes women who are post-menopausal for at least 12 months after the last menses. FCBP must agree to use a medically acceptable form of birth control during the study and for at least 6 months after discontinuation of Erbitux® or study medication. Females must agree not to breast feed during the study and for at least two months after discontinuation of Erbitux® or study medication. Male patients should be using a double barrier protection method that is a medically acceptable form of birth control during the study or be sterile. 5. Patients must have an ECOG score of 0 - 2. 6. Patient must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure. Exclusion Criteria: Patients with any of the following will be excluded from participation in the study: 1. Patients with a history of significant Erbitux infusion reactions (= Grade 3). 2. Patients on chemotherapy or Erbitux® therapy or radiation therapy within 4 weeks of enrollment. 3. Tumor invading a major blood vessel (such as the carotid artery) unless the vessel has been embolized, stented or surgically ligated to prevent hemorrhage. 4. Tumor is not clearly shown on a CT scan or clinically measurable. 5. Location and extension of the tumor precludes an effective PIT. 6. Patients with impaired hepatic function (ALP (hepatic), AST and/or ALT >3 times the upper normal limits, or total serum bilirubin > 2 mg/dL. 7. Patients with impairment of renal function (serum creatinine >2 mg/dL). 8. Unwilling or unable to follow protocol requirements. 9. Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug. 10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 11. Patient requires examinations or treatments within 4 weeks after study drug administration where they would be exposed to significant light, e.g., eye examinations, surgical procedures, endoscopy, etc. |
Country | Name | City | State |
---|---|---|---|
United States | Rush University Cancer Center | Chicago | Illinois |
United States | Centura Health Research Center | Denver | Colorado |
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Virginia Piper Cancer Institute, part of Allina Health System | Minneapolis | Minnesota |
United States | University of Oklahoma Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Rakuten Medical, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part I: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) of RM-1929, whichever is lowest | Determine the MTD or MFD of RM-1929 | 1 month | |
Primary | Part I: Adverse Event profile for each drug dose of RM-1929 | Assessment of safety of the combination of drug dose with low energy localized light irradiation | 1 month | |
Primary | Part I: Photosafety (sunburn) Testing | Determination of skin Minimal Erythema Dose (MED) following infusion of RM-1929 | 1 month | |
Primary | Part II: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) of a fixed drug dose with fixed light dose | Determination of MTD or MFD of fixed drug dose with fixed light dose | 1 month | |
Primary | Part II: Safety with repeat dosing | Safety parameters associated with repeat dosing | 2 years or until death | |
Secondary | Part I: Tumor response | Document tumor response using response assessment in solid tumors version 1.1 (RECIST 1.1), including additional assessment of target lesion volumetrics | 2 months | |
Secondary | Part 1: Tumor reduction/necrosis | Document tumor reduction/necrosis using Choi criteria | 2 month | |
Secondary | Part I: Pharmacokinetics of RM-1929 and for both RM-1929 and unconjugated IRDye 700DX (Cmax, T 1/2, AUC, CL and Vss) | 1 month | ||
Secondary | Part I: Immunogenic response to RM-1929 | To assess antibodies to RM-1929 or cetuximab | 2 month | |
Secondary | Part II: Tumor Response | Assessed using RECIST 1.1 | 2 months | |
Secondary | Part II: Tumor Reduction | Evaluation by CT scans, clinical measurement, photographs, biopsies, symptom relief and ECOG performance | 2 months | |
Secondary | Part II: Immunogenic response to RM-1929 | To assess antibodies to RM-1929 or cetuximab | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05738187 -
Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study
|
N/A | |
Recruiting |
NCT02567383 -
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05980000 -
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03691714 -
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02842125 -
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT04969861 -
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04260126 -
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
|
Phase 2 | |
Completed |
NCT02358031 -
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
|
Phase 3 | |
Completed |
NCT04902027 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers
|
Phase 1 | |
Recruiting |
NCT04534205 -
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
|
Phase 2 | |
Active, not recruiting |
NCT02289209 -
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT06239220 -
PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
|
Phase 2 | |
Recruiting |
NCT04673929 -
Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
|
||
Recruiting |
NCT03754933 -
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT03937141 -
Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT00088907 -
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
|
Phase 3 | |
Completed |
NCT01620242 -
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes
|
Phase 2 | |
Terminated |
NCT01606566 -
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
|
Phase 2 | |
Completed |
NCT01255800 -
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
|
Phase 1 |